{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:05:51Z","timestamp":1790730351725,"version":"4.1.0"},"reference-count":47,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"unspecified","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,3,1]]},"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Colorectal cancer (CRC) is the third most common cancer type and one of the leading causes of cancer-related death worldwide. The treatment of advanced metastatic CRC relies on classical chemotherapy combinations (5-fluorouracil, oxaliplatin or irinotecan). However, their use is limited by the emergence of resistance mechanisms, including to oxaliplatin. In this context, we recently showed that the combination of oxaliplatin and ataxia telangiectasia and Rad3-related protein inhibition (VE-822) is synergistic and may have a potential therapeutic effect in metastatic CRC management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we investigated the role of the VE-822+oxaliplatin (Vox) combination on the immune response and its potential synergy with an anti-programmed-cell Death receptor-1 (PD-1) antibody. We used cell lines and organoids from metastatic CRC to investigate in vitro Vox efficacy and orthotopic syngeneic mouse models of metastatic CRC to assess the efficacy of Vox+anti-PD-1 antibody and identify the involved immune cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The Vox+anti-PD-1 antibody combination completely cured tumor-bearing mice and protected them from a rechallenge. Vox was associated with a reduction of tumor-infiltrated neutrophils, CD206\n                      <jats:sup>+<\/jats:sup>\n                      macrophages and regulatory T cells. Vox also induced a deep depletion of blood neutrophils. The increased bone marrow granulopoiesis failed to compensate for the Vox-mediated mature neutrophil depletion. Neutrophil depletion using a mouse recombinant anti-Ly6G antibody partially mimicked the Vox effect on the tumor microenvironment, but to a lower extent compared with the Vox+anti-PD-1 antibody combination. Vox, but not neutrophil depletion, led to the emergence of an Ly6C\n                      <jats:sup>+<\/jats:sup>\n                      PD-1\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell population in the blood and spleen of tumor-harboring mice. These cells were proliferating, and expressed IFN-\u03b3, CD62L, CXCR3 and Eomes. Moreover, the proportion of tumor antigen-specific T cells and of CD122\n                      <jats:sup>+<\/jats:sup>\n                      BCL6\n                      <jats:sup>+<\/jats:sup>\n                      T cells, which shared phenotypic characteristics with stem-like CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, was increased in treated mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our work strongly suggests that the Vox+anti-PD-1 antibody combination might significantly improve survival in patients with metastatic and treatment-refractory CRC by acting both on cancer cells and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2024-010791","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T03:00:06Z","timestamp":1743044406000},"page":"e010791","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechallenge in mice"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct04221464","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04221464","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8967-7538","authenticated-orcid":false,"given":"Alexandra","family":"Fauvre","sequence":"first","affiliation":[{"name":"R\u00e9sistance aux traitements et th\u00e9rapies innovantes, Institut de Recherche en Canc\u00e9rologie de Montpellier (IRCM), Universit\u00e9 de Montpellier (UM), CNRS, Institut R\u00e9gional du Cancer de Montpellier (ICM), Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ursino","sequence":"additional","affiliation":[{"name":"Immunity and Cancer Team, Institut de Recherche en Canc\u00e9rologie de Montpellier (IRCM), Universit\u00e9 de Montpellier (UM), Institut R\u00e9gional du Cancer de Montpellier (ICM), Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Garambois","sequence":"additional","affiliation":[{"name":"R\u00e9sistance aux traitements et th\u00e9rapies innovantes, Institut de Recherche en Canc\u00e9rologie de Montpellier (IRCM), Universit\u00e9 de Montpellier (UM), CNRS, Institut R\u00e9gional du Cancer de Montpellier (ICM), Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Culerier","sequence":"additional","affiliation":[{"name":"Immunity and Cancer Team, Institut de Recherche en Canc\u00e9rologie de Montpellier (IRCM), Universit\u00e9 de Montpellier (UM), Institut R\u00e9gional du Cancer de Montpellier (ICM), Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8155-9021","authenticated-orcid":false,"given":"Louis-Antoine","family":"Milazzo","sequence":"additional","affiliation":[{"name":"R\u00e9sistance aux traitements et th\u00e9rapies innovantes, Institut de Recherche en Canc\u00e9rologie de Montpellier (IRCM), Universit\u00e9 de Montpellier (UM), CNRS, Institut R\u00e9gional du Cancer de Montpellier (ICM), Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Vezzio-Vi\u00e9","sequence":"additional","affiliation":[{"name":"R\u00e9sistance aux traitements et th\u00e9rapies innovantes, Institut de Recherche en Canc\u00e9rologie de Montpellier (IRCM), Universit\u00e9 de Montpellier (UM), CNRS, Institut R\u00e9gional du Cancer de Montpellier (ICM), Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Jeanson","sequence":"additional","affiliation":[{"name":"R\u00e9sistance aux traitements et th\u00e9rapies innovantes, Institut de Recherche en Canc\u00e9rologie de Montpellier (IRCM), Universit\u00e9 de Montpellier (UM), CNRS, Institut R\u00e9gional du Cancer de Montpellier (ICM), Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice","family":"Marchive","sequence":"additional","affiliation":[{"name":"R\u00e9sistance aux traitements et th\u00e9rapies innovantes, Institut de Recherche en Canc\u00e9rologie de Montpellier (IRCM), Universit\u00e9 de Montpellier (UM), CNRS, Institut R\u00e9gional du Cancer de Montpellier (ICM), Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto Faria","family":"Andrade","sequence":"additional","affiliation":[{"name":"McGill University\/Research Institute of McGill University, Nada Jabado Lab, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7145-7599","authenticated-orcid":false,"given":"Eve","family":"Combes","sequence":"additional","affiliation":[{"name":"R\u00e9sistance aux traitements et th\u00e9rapies innovantes, Institut de Recherche en Canc\u00e9rologie de Montpellier (IRCM), Universit\u00e9 de Montpellier (UM), CNRS, Institut R\u00e9gional du Cancer de Montpellier (ICM), Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salima","family":"Atis","sequence":"additional","affiliation":[{"name":"R\u00e9sistance aux traitements et th\u00e9rapies innovantes, Institut de Recherche en Canc\u00e9rologie de Montpellier (IRCM), Universit\u00e9 de Montpellier (UM), CNRS, Institut R\u00e9gional du Cancer de Montpellier (ICM), Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rald","family":"Lossaint","sequence":"additional","affiliation":[{"name":"Institut regional du Cancer de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Quenet","sequence":"additional","affiliation":[{"name":"Institut regional du Cancer de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6165-1929","authenticated-orcid":false,"given":"Henri-Alexandre","family":"Michaud","sequence":"additional","affiliation":[{"name":"Immunity and Cancer Team, Institut de Recherche en Canc\u00e9rologie de Montpellier (IRCM), Universit\u00e9 de Montpellier (UM), Institut R\u00e9gional du Cancer de Montpellier (ICM), Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakhdar","family":"Khellaf","sequence":"additional","affiliation":[{"name":"Department of Pathology, Montpellier University, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana","family":"Corbeau","sequence":"additional","affiliation":[{"name":"Institut regional du Cancer de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0401-7400","authenticated-orcid":false,"given":"Diego","family":"Tosi","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Institut r\u00e9gional du Cancer de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Houede","sequence":"additional","affiliation":[{"name":"Department of Oncology, University Hospital of Nimes, N\u00eemes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4814-6722","authenticated-orcid":false,"given":"Nathalie","family":"Bonnefoy","sequence":"additional","affiliation":[{"name":"Immunity and Cancer Team, Institut de Recherche en Canc\u00e9rologie de Montpellier (IRCM), Universit\u00e9 de Montpellier (UM), Institut R\u00e9gional du Cancer de Montpellier (ICM), Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6965-3697","authenticated-orcid":false,"given":"Olivia","family":"Sgarbura","sequence":"additional","affiliation":[{"name":"Institut regional du Cancer de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9034-4031","authenticated-orcid":false,"given":"C\u00e9line","family":"Gongora","sequence":"additional","affiliation":[{"name":"R\u00e9sistance aux traitements et th\u00e9rapies innovantes, Institut de Recherche en Canc\u00e9rologie de Montpellier (IRCM), Universit\u00e9 de Montpellier (UM), CNRS, Institut R\u00e9gional du Cancer de Montpellier (ICM), Montpellier, France"},{"name":"CNRS, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0848-7135","authenticated-orcid":false,"given":"Julien","family":"Faget","sequence":"additional","affiliation":[{"name":"Immunity and Cancer Team, Institut de Recherche en Canc\u00e9rologie de Montpellier (IRCM), Universit\u00e9 de Montpellier (UM), Institut R\u00e9gional du Cancer de Montpellier (ICM), Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"2026052722304548000_13.3.e010791.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2026052722304548000_13.3.e010791.2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.dld.2024.06.018","article-title":"Trends in incidence of infrequent and frequent synchronous metastases from colorectal cancer","volume":"57","author":"Jooste","year":"2025","journal-title":"Dig Liver Dis"},{"key":"2026052722304548000_13.3.e010791.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30500-9"},{"key":"2026052722304548000_13.3.e010791.4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq222"},{"key":"2026052722304548000_13.3.e010791.5","doi-asserted-by":"crossref","first-page":"1756284820917527","DOI":"10.1177\/1756284820917527","article-title":"Advances in immunotherapy for colorectal cancer: a review","volume":"13","author":"Golshani","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"key":"2026052722304548000_13.3.e010791.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2901-x"},{"key":"2026052722304548000_13.3.e010791.7","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.356"},{"key":"2026052722304548000_13.3.e010791.8","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-024-03641-5","article-title":"Immunogenic cell death in colorectal cancer: a review of mechanisms and clinical utility","volume":"73","author":"De Silva","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"2026052722304548000_13.3.e010791.9","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/S0007-4551(18)30395-3","article-title":"Nouvelles strat\u00e9gies innovantes en immunoth\u00e9rapie","volume":"105","author":"Ghiringhelli","year":"2018","journal-title":"Bull Cancer"},{"key":"2026052722304548000_13.3.e010791.10","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.omtm.2020.12.013","article-title":"Inhibition of indoleamine 2,3-dioxygenase 1 synergizes with oxaliplatin for efficient colorectal cancer therapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2026052722304548000_13.3.e010791.11","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-2807"},{"key":"2026052722304548000_13.3.e010791.12","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1522607"},{"key":"2026052722304548000_13.3.e010791.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-018-0034-3"},{"key":"2026052722304548000_13.3.e010791.14","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0019"},{"key":"2026052722304548000_13.3.e010791.15","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-21-2997","article-title":"ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib","volume":"82","author":"Wilson","year":"2022","journal-title":"Cancer Res"},{"key":"2026052722304548000_13.3.e010791.16","article-title":"Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation","volume":"134","author":"Dillon","year":"2024","journal-title":"J Clin"},{"key":"2026052722304548000_13.3.e010791.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1821"},{"key":"2026052722304548000_13.3.e010791.18","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-45996-4","article-title":"The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment","volume":"15","author":"Hardaker","year":"2024","journal-title":"Nat Commun"},{"key":"2026052722304548000_13.3.e010791.19","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jtho.2022.07.074","article-title":"OA15.05 HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed Phase 2 Study in NSCLC Patients Who Progressed on Anti-PD-(L)1 Therapy","volume":"17","author":"Besse","year":"2022","journal-title":"J Thorac Oncol"},{"key":"2026052722304548000_13.3.e010791.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.10.009"},{"key":"2026052722304548000_13.3.e010791.21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005041","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer","volume":"10","author":"Kwon","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026052722304548000_13.3.e010791.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0101-z"},{"key":"2026052722304548000_13.3.e010791.23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fmed.2015.00088","article-title":"Therapeutic Efficacy of Alpha-RIT Using a 213Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal Carcinomatosis","volume":"2","author":"Derrien","year":"2015","journal-title":"Front Med"},{"key":"2026052722304548000_13.3.e010791.24","unstructured":"Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma - gourdier - 2002 - febs letters - wiley online library. Available: https:\/\/febs.onlinelibrary.wiley.com\/doi\/full\/10.1016\/S0014-5793%2802%2903347-1?sid=nlm%3Apubmed [Accessed 20 Aug 2024]."},{"key":"2026052722304548000_13.3.e010791.25","first-page":"1307","article-title":"Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing","volume":"8","author":"Sun","year":"2018","journal-title":"Am J Cancer Res"},{"key":"2026052722304548000_13.3.e010791.26","first-page":"1400","article-title":"NK cell-produced IFN-\u03b3 regulates cell growth and apoptosis of colorectal cancer by regulating IL-15","volume":"19","author":"Cui","year":"2020","journal-title":"Exp Ther Med"},{"key":"2026052722304548000_13.3.e010791.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.11.007"},{"key":"2026052722304548000_13.3.e010791.28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007939","article-title":"CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value","volume":"12","author":"Battaglin","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026052722304548000_13.3.e010791.29","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17050643","article-title":"The Role of Chemokines in Promoting Colorectal Cancer Invasion\/Metastasis","volume":"17","author":"Itatani","year":"2016","journal-title":"Int J Mol Sci"},{"key":"2026052722304548000_13.3.e010791.30","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.12811"},{"key":"2026052722304548000_13.3.e010791.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.04.040"},{"key":"2026052722304548000_13.3.e010791.32","doi-asserted-by":"crossref","DOI":"10.3390\/cells11213406","article-title":"Effective, Long-Term, Neutrophil Depletion Using a Murinized Anti-Ly-6G 1A8 Antibody","volume":"11","author":"Olofsen","year":"2022","journal-title":"Cells"},{"key":"2026052722304548000_13.3.e010791.33","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg7836","article-title":"A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response","volume":"6","author":"Connolly","year":"2021","journal-title":"Sci Immunol"},{"key":"2026052722304548000_13.3.e010791.34","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/cac2.12412","article-title":"Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer","volume":"43","author":"Liu","year":"2023","journal-title":"Cancer Commun"},{"key":"2026052722304548000_13.3.e010791.35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000340","article-title":"ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma","volume":"8","author":"Sheng","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026052722304548000_13.3.e010791.36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30599-4"},{"key":"2026052722304548000_13.3.e010791.37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000492678","article-title":"Compromised DNA Repair and Signalling in Human Granulocytes","volume":"11","author":"Ponath","year":"2019","journal-title":"J Innate Immun"},{"key":"2026052722304548000_13.3.e010791.38","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgx002"},{"key":"2026052722304548000_13.3.e010791.39","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s12185-017-2300-7","article-title":"The DNA damage response pathway in normal hematopoiesis and malignancies","volume":"106","author":"Delia","year":"2017","journal-title":"Int J Hematol"},{"key":"2026052722304548000_13.3.e010791.40","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002242","article-title":"Neutrophils in the era of immune checkpoint blockade","volume":"9","author":"Faget","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026052722304548000_13.3.e010791.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.09.005"},{"key":"2026052722304548000_13.3.e010791.42","doi-asserted-by":"crossref","first-page":"100554","DOI":"10.1016\/j.xcrm.2022.100554","article-title":"AXL targeting restores PD-1 blockade sensitivity of STK11\/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells","volume":"3","author":"Li","year":"2022","journal-title":"Cell Reports Medicine"},{"key":"2026052722304548000_13.3.e010791.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.12.021"},{"key":"2026052722304548000_13.3.e010791.44","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg6895","article-title":"Lung dendritic cells migrate to the spleen to prime long-lived TCF1hi memory CD8+ T cell precursors after influenza infection","volume":"6","author":"Jenkins","year":"2021","journal-title":"Sci Immunol"},{"key":"2026052722304548000_13.3.e010791.45","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adh1306","article-title":"BCL6 promotes a stem-like CD8+ T cell program in cancer via antagonizing BLIMP1","volume":"8","author":"Sun","year":"2023","journal-title":"Sci Immunol"},{"key":"2026052722304548000_13.3.e010791.46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02808-y"},{"key":"2026052722304548000_13.3.e010791.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02399-0"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-010791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T05:31:22Z","timestamp":1779946282000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-010791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,26]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1136\/jitc-2024-010791"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-010791","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]}}}